Synergy CHC Corp. Common Stock (SNYR)
FairStock Score: 16/100 — RISKY
Key Financials
| Current Price | $0.01 |
| Market Cap | $5M |
| P/E Ratio | -0.01 |
| ROE | —% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Mr. Market is offering this at one cent as of 2026-09-28, a $4.6 million market cap. That is a distressed price, not a bargain label. The company sells consumer health and wellness brands—FOCUSfactor, Flat Tummy, Hand MD, Neuragen—through a small 28-employee operation. In fiscal Q1 2026, revenue was $5.5 million and net income was -$2.6 million, a -46.77% net margin. The provided filed figures show revenue growth of -32.77% and profit growth of -393.16%, so the trajectory is shrinking and deeply unprofitable. Trailing free cash flow is -$3.8 million, and FairStock calculates an FCF yield of -83.2% against the current market cap. FairStock's P/E is -0.01, ROCE is -62.02%, Piotroski F-Score is 5/9, Altman Z-Score is -12.23, and FairStock Score is 16/100. Those are not the marks of a durable business. I see little evidence of a moat: the brands may have shelf space, but the numbers show no pricing power or cost discipline. With no P/B or D/E data provided, I cannot judge asset value or leverage, but the Altman Z-Score screams financial distress. The Lynch category is none because only 0 years of filed results are available and three are needed. Valuation is almost impossible on earnings; the P/E is negative. At this price, the market is pricing in severe doubt. I would demand stabilization in revenue, narrower losses, and positive cash generation before trusting the equity.
In plain English: Synergy CHC sells consumer health, beauty, and lifestyle products under brands such as FOCUSfactor, Flat Tummy, Hand MD, and Neuragen. The business looks weak: sales are falling, it is losing money, and it burns cash. The stock price is a penny, which looks very cheap, but the weak financials make it a speculative situation rather than an obvious bargain.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-09-28 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer